NPI: 1285200105 · COLUMBIA, SC 29203 · General Acute Care Hospital · NPI assigned 06/01/2021
Authorized official RAE, KARYN controls 20+ related entities in our dataset. Read more
| Authorized Official | RAE, KARYN (CHIEF) |
| NPI Enumeration Date | 06/01/2021 |
Other providers sharing the same authorized official: RAE, KARYN
| Year | Claims | Total Paid |
|---|---|---|
| 2021 | 25,309 | $933K |
| 2022 | 51,413 | $1.38M |
| 2023 | 53,684 | $1.36M |
| 2024 | 42,733 | $996K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 80053 | Comprehensive metabolic panel | 9,031 | 8,094 | $894K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7,241 | 6,810 | $595K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 5,588 | 5,325 | $547K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3,730 | 2,831 | $418K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2,762 | 2,456 | $230K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 306 | 223 | $229K |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 12,929 | 12,041 | $158K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2,143 | 1,918 | $126K |
| 36415 | Collection of venous blood by venipuncture | 10,802 | 9,259 | $118K |
| 81003 | 4,389 | 3,958 | $99K | |
| 70450 | Computed tomography, head or brain; without contrast material | 2,092 | 1,929 | $86K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3,238 | 2,910 | $64K |
| 81025 | 4,776 | 4,484 | $57K | |
| 87210 | 614 | 594 | $56K | |
| 87430 | 477 | 414 | $53K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1,304 | 1,248 | $47K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1,554 | 446 | $46K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 236 | 212 | $44K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1,060 | 885 | $42K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 201 | 162 | $37K |
| 71045 | Radiologic examination, chest; single view | 4,480 | 4,091 | $37K |
| 73630 | 477 | 439 | $35K | |
| 81001 | 4,189 | 3,936 | $35K | |
| 73130 | 375 | 342 | $35K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 282 | 275 | $34K |
| 73560 | 781 | 670 | $33K | |
| 99284 | Emergency department visit for the evaluation and management, high severity | 7,283 | 6,826 | $33K |
| 71046 | Radiologic examination, chest; 2 views | 1,372 | 1,289 | $32K |
| 73610 | 359 | 333 | $32K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 427 | 361 | $28K |
| 84702 | 692 | 636 | $27K | |
| 73030 | 419 | 390 | $26K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1,493 | 1,470 | $25K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 685 | 623 | $25K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2,286 | 2,104 | $18K |
| 72100 | 465 | 443 | $18K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 507 | 487 | $17K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1,090 | 1,010 | $17K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4,682 | 4,257 | $16K |
| 86900 | 90 | 86 | $14K | |
| 97597 | 228 | 139 | $14K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 96 | 95 | $13K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 10,938 | 9,713 | $13K |
| 73110 | 115 | 109 | $12K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 918 | 845 | $12K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 83 | 83 | $11K |
| A9585 | Injection, gadobutrol, 0.1 ml | 12 | 12 | $11K |
| 82947 | 771 | 560 | $8K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1,886 | 1,762 | $8K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 602 | 581 | $7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 285 | 237 | $7K |
| 88304 | 149 | 148 | $6K | |
| 87077 | 129 | 95 | $5K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 178 | 148 | $5K |
| 72040 | 76 | 75 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | 462 | 432 | $4K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 4,650 | 4,173 | $3K |
| 74018 | 27 | 25 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 675 | 651 | $3K |
| 86140 | 84 | 74 | $3K | |
| 87420 | 67 | 54 | $2K | |
| 10060 | 15 | 13 | $2K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 246 | 94 | $2K |
| 82962 | 35 | 31 | $2K | |
| 83690 | 3,322 | 3,045 | $1K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 240 | 218 | $1K |
| 84484 | 3,829 | 3,088 | $1K | |
| 73502 | 25 | 25 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 12 | 12 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 107 | 97 | $1K |
| A9270 | Non-covered item or service | 2,137 | 1,778 | $1K |
| 93971 | 64 | 61 | $1K | |
| 85379 | 1,354 | 1,286 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 16 | 15 | $916.42 |
| 83735 | 3,318 | 2,936 | $837.52 | |
| 73590 | 15 | 13 | $774.79 | |
| 84703 | 719 | 695 | $765.13 | |
| 85027 | 755 | 620 | $758.79 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 773 | 709 | $736.21 |
| 96375 | Therapeutic injection; each additional sequential IV push | 2,733 | 2,380 | $624.02 |
| 84443 | Thyroid stimulating hormone (TSH) | 631 | 598 | $434.49 |
| 83036 | Hemoglobin; glycosylated (A1C) | 102 | 97 | $426.84 |
| 83880 | 769 | 690 | $404.16 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 1,148 | 855 | $376.73 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1,002 | 969 | $297.00 |
| G0378 | Hospital observation service, per hour | 155 | 77 | $235.85 |
| 85610 | 371 | 313 | $215.38 | |
| 87081 | 437 | 381 | $200.23 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1,281 | 1,216 | $132.92 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 1,646 | 1,466 | $46.87 |
| 83605 | 237 | 207 | $43.60 | |
| 96376 | 578 | 459 | $41.27 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1,445 | 1,301 | $29.85 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 3,748 | 3,394 | $28.47 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 3,322 | 3,050 | $22.26 |
| 84100 | 40 | 36 | $12.83 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 184 | 163 | $5.96 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1,486 | 1,388 | $5.27 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 317 | 298 | $1.87 |
| J2704 | Injection, propofol, 10 mg | 1,448 | 785 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 891 | 765 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 153 | 128 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 186 | 179 | $0.00 |
| 82077 | 12 | 12 | $0.00 | |
| 87040 | 73 | 43 | $0.00 | |
| 86901 | 90 | 86 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 255 | 225 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 45 | 41 | $0.00 |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 69 | 24 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 39 | 39 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 62 | 56 | $0.00 |
| 85730 | 44 | 41 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 162 | 132 | $0.00 |
| 94644 | 14 | 12 | $0.00 | |
| 80320 | 15 | 12 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 38 | 29 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 17 | 12 | $0.00 |
| 85651 | 16 | 13 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 363 | 320 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 807 | 699 | $0.00 |
| 90715 | 75 | 67 | $0.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 21 | 17 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 61 | 41 | $0.00 |
| 87631 | 16 | 12 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 32 | 25 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 57 | 45 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 37 | 31 | $0.00 |
| 87186 | 53 | 43 | $0.00 | |
| 80076 | 23 | 19 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 13 | 12 | $0.00 |